Sector News

UCB enters drug discovery collaboration with Aitia

March 19, 2023
Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia.

The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

It will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing new therapies discovery for Huntington’s disease patients.

UCB executive vice-president and chief scientific officer Dhaval Patel said: “We are pleased to work with Aitia in a bid to unravel the circuity of this debilitating disease.

“We see this collaboration as an investment in next-generation science and technology, allowing us to accelerate our understanding of human pathobiology and explore the potential of developing novel medicines through AI.”

According to the company, Huntington’s disease affects nearly one in 10,000 people across the world.

At present, there is no cure for the disease, with limited treatment options.

Aitia CEO and co-founder Colin Hill said: “At Aitia, our mission is to discover the next generation of breakthrough drugs to improve outcomes for patients where there is a high unmet need.

“We believe that Huntington’s disease is overdue for major disruption and breakthroughs from our Gemini Digital Twins which are created from large quantities of multi-omic patient data and causal AI.

“We’re excited to collaborate closely with UCB to gain deeper insights into the underlying mechanisms of this complex disease and hope to drive major advancements in drug discovery and development faster than ever before.”

The company is exposing the hidden biological mechanisms of disease for developing Digital Twins of disease in immunology, neurodegenerative disorders, and oncology by using the convergence of multi-omic patient data, causal learning and AI and high-performance computing.

Source: pharmaceutical-technology.com

 

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach